We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
62 hedge funds and large institutions have $397M invested in Entrada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
13% more funds holding
Funds holding: 55 → 62 (+7)
0.65% more ownership
Funds ownership: 78.26% → 78.91% (+0.65%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less capital invested
Capital invested by funds: $411M → $397M (-$14M)
Holders
62
Holders Change
+7
Holders Change %
+12.73%
% of All Funds
0.9%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
10
Increased
22
Reduced
14
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
+$1.56M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$1.48M |
| 3 |
BlackRock
New York
|
+$1.45M |
| 4 |
Morgan Stanley
New York
|
+$1.15M |
| 5 |
Bank of New York Mellon
New York
|
+$713K |
